Dr. Alan List is the president and CEO of Moffitt Cancer Center. He is a senior member in the Department of Malignant Hematology and the Experimental Therapeutics Program. In addition, Dr. List is a professor of internal medicine and oncology at the University of South Florida College of Medicine.
Dr. List’s research interests include novel therapeutic agents to treat acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He and his research team are nationally recognized for their contributions to understanding the biology of AML and MDS in order to develop more effective treatment strategies.
The former leader of Moffitt’s Malignant Hematology Program, Dr. List was the lead investigator for a study that showed important clinical results for Revlimid, which has received fast-track designation from the U.S. Food and Drug Administration to treat MDS and multiple myeloma.
After earning his medical degree from the University of Pennsylvania, Dr. List completed a residency in medicine at Good Samaritan Medical Center in Phoenix, AZ. He pursued fellowships in hematology and oncology at Vanderbilt University Medical Center in Nashville, Tenn.
Prior to joining Moffitt in 2003, Dr. List was a professor of medicine and director of the Leukemia and Bone Marrow Transplant Program at the University of Arizona Tucson, as well as director of the Division of Translational/Clinical Research.